Ecron Acunova

Ecron Acunova was a leading India-based contract research organization specializing in end-to-end services for generic drug development. The company conducted over 1500 bioequivalence studies with more than 100 marketing authorizations obtained globally. It supported Abbreviated New Drug Applications via both the US FDA’s ANDA pathways—505(j) and complex generics under the hybrid pathway—and provided comprehensive services including study design, conduct, data management, regulatory support, pharmacovigilance, and central lab services. The company was known for its strong compliance record with GCP/GLP standards and certifications such as ISO9001/ISO27001/NABL/CAP. Ecron Acunova was acquired by TAKE Solutions Limited; some subsidiaries have since ceased operations.